This is the authors' abstract. We don't add key points for this paper.
Psoriasis is a common inflammatory skin disease, but its pathogenesis is unknown. This paper presents 2 cases of psoriasis vulgaris in which the skin lesions were improved for 3 months and more after the start of oral treatment with 1α,25‐dihydroxyvitamin D3 at a dose of 0.5 μg/day. The circulating levels of calcium, inorganic phosphate, 25‐hydroxyvitamin D, 1α,25‐dihydroxyvitamin D, parathyroid hormone and calcitonin were within normal ranges before and after the start of treatment. These findings suggest that 1α,25‐dihydroxyvitamin D3 has a beneficial effect on psoriatic skin lesions. It probably has a direct effect on enhancing epidermal cell differentiation. Abbreviations: Ca: calcium, hCT: calcitonin, 25‐OHD: 25‐hydroxyvitamin D, 1,25‐(OH)2D: 1α,25‐dihydroxyvitamin D, 1,25‐(OH)2D3: 1α,25‐dihydroxyvitamin D3, Pi: inorganic phosphate
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Morimoto et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: